AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06317805
Drug: Standard of Care - Double Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive standard of care double oral background treatment consisting of one Phosphodiesterase type 5 inhibitor (i.e., tadalafil or sildenafil) and one Endothelin Receptor Antagonist (i.e. ambrisentan, bosentan or macitentan)
Trial: NCT06531707
Drug: Ibuprofen + Loratadine fixed dose
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suspension 8,000 mg / 100 mg / 100 mL, 5 mL twice a day
Trial: NCT06531707
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Suspension 2,000 mg / 100 mL, 20 mL twice a day
Trial: NCT05457270
Drug: AZD4831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of AZD4831 Formulation A Or a single oral dose of AZD4831 Formulation B on Day 1 of Period 2. Each period lasts for 8 days.
Trial: NCT04374474
Drug: corticosteroid nasal irrigation
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).
Trial: NCT05484401
Drug: Ibuprofen 200Mg Oral Cap
RxNorm normalized name: IBUPROFEN 200MG ORAL CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 200mg Liquid Capsules once in 12 hours
Trial: NCT05484401
Drug: Ibuprofen 200Mg Oral Tablet
RxNorm normalized name: Ibuprofen 200mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 200mg Tablets once in 12 hours
Trial: NCT04878705
Drug: TWP-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single subcutaneous injection
Trial: NCT04878705
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single subcutaneous injection
Trial: NCT06391827
Drug: DA-7503 Single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration for once; Dose strength is different for each cohort(Cohort 1, 2, 3, 4 and 5).
Trial: NCT06391827
Drug: Placebo Single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administraion for once.
Trial: NCT06391827
Drug: Placebo Multiple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily for 7 days
Trial: NCT05322603
Drug: Analgesics Non Opioid (Neodolpasse manufactured by Fresenius Kabi)
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A decrease in the pain severity (VAS);opioid-sparing effect
Trial: NCT05322603
Drug: Analgesics
RxNorm normalized name: ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A decrease in the pain severity (VAS)
Trial: NCT00863538
Drug: KPS-0373
RxNorm normalized name: Draxxin KP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05160805
Drug: ONL1204 Ophthalmic solution (Dose A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation administered by intravitreal (IVT) injection
Trial: NCT05663398
Drug: Darfen 400, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, a nonsteroidal anti-inflammatory drug
Trial: NCT05663398
Drug: Nurofen® Forte Express, 400 mg ibuprofen coated tablets (512 mg ibuprofen sodium dihydrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, a nonsteroidal anti-inflammatory drug
Trial: NCT04825223
Drug: Multicomponent Meningococcal B Vaccine
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Liquid suspension for injection in a single vial Four liquid suspensions and one diluent (only for Stage 1) Route of administration: Intramuscular
Trial: NCT04825223
Drug: Meningococcal Group B Vaccine MenB
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
Trial: NCT04825223
Drug: Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Liquid suspension for injection in a pre-filled syringe Route of administration: Intramuscular
Trial: NCT04825223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
Trial: NCT06406205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo softgel capsules, identical to 7.9 mg QL1074, will be provided. The administration plan and dosage management regulations are the same as QL1074.
Trial: NCT06205290
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06293417
Drug: Dose escalation of moderate-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group
Trial: NCT05768503
Drug: Experimental drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment option for the chidamide + sintilimab + bevacizumab is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
Trial: NCT06531759
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl soaked nasal packs.
Trial: NCT06429306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl triethyl citrate
Trial: NCT05039905
Drug: 99mTc-MSA-ICG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral injection of 99mTechnetium-manosylated albumin-indocyanine green to lung cancer patients
Trial: NCT04902105
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: NCT04760275
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This will be a single-blind SMART design of 24 weeks duration that will employ two sequential levels of randomization, one in each of two 12-week stages of the study.~In Stage 1, participants will be randomized 1:1 to receive 12 weeks of the medication fluoxetine in upward-titrated dosages. In Stage 2, also 12 weeks in duration, participants who remit during the first 12 weeks of treatment will continue maintenance-level therapy with fluoxetine. All participants who do not remit will be randomized (1:1) to either (1) optimization of fluoxetine (increasing the dose of fluoxetine as tolerated), or (2) optimization of fluoxetine and addition of Cognitive Behavioral Therapy (CBT).
Trial: NCT06664008
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc used a supplement due to its role in decreasing inflammation of the gastroesophageal reflux disease.
Trial: NCT04372615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will receive IV matching placebo on Day 1 and Day 15,
Trial: NCT05044234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral
Trial: NCT04901117
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use according to the drug combination options selected by each center.
Trial: NCT04901117
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use according to the drug combination options selected by each center.
Trial: NCT04528563
Drug: Ketorolac Tromethamine 10 MG/ML
RxNorm normalized name: ketorolac tromethamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Steroidal-Anti-Inflammatory given intravenously.
Trial: NCT05294263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching, inactive medication
Trial: NCT06026566
Drug: Dos of Afentanil 50
RxNorm normalized name: purified protein derivative of tuberculin 50 UNT/ML [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the dosage of Afentanil is 50 ng/ml for TCI
Trial: NCT06404177
Drug: Piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intramuscular injection of piroxicam with a perfusion of isotonic saline intravenous
Trial: NCT04978038
Drug: mRNA- COVID-19
RxNorm normalized name: COVID-19 VACCINE MRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer-BioNtech mRNA- COVID-19 0.3ml dose administered intramuscularly
Trial: NCT05372198
Drug: Chohort 2: Immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refer to the instructions for the use of immunotherapy, every 3 weeks as a cycle
Trial: NCT05130567
Drug: LP-128 capsules
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing with LP-128 capsules
Trial: NCT05855200
Drug: CAPEOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPEOX will be administered.
Trial: NCT05855200
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX will be administered.
Trial: NCT06394128
Drug: Cangpo Liujun Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on the diagnostic criteria of spleen deficiency and dampness excess syndrome, Cangpo Liujun Prescription could be used to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy.
Trial: NCT05468840
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see study arm description
Trial: NCT05932290
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care
Trial: NCT05916755
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard NACT will be given.
Trial: NCT05378867
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The mFOLFOX6 regimen is:~* Oxaliplatin, 85 mg/m2 administered IV over 2 hours~* LCV, 400 mg/m2 administered over 2 hours concurrent with oxaliplatin~* 5-FU, 400 mg/m2 given as a slow IV push (bolus) over 5 minutes administered immediately after LCV~* 5-FU, 2400 mg/m2 administered IV over 46 hours by infusion pump beginning immediately after FU IV bolus.
Trial: NCT05297045
Drug: RGT001-075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GLP1 Receptor Agonist
Trial: NCT06396065
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Placebo Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles in treatment periods per the randomization schedule. Afterward, Placebo Plus Pemetrexed will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W) up to 2 years.
Trial: NCT06168175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous, daily for 5 consecutive days
Trial: NCT05434897
Drug: AK3280 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: AK3280, Pharmaceutical Form:Cream, Route of Administration: External use
Trial: NCT05434897
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: Placebo, Pharmaceutical Form: Cream, Route of Administration: External use
Trial: NCT04725175
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple ascending oral doses of matching Placebo tablets
Trial: NCT05035979
Drug: BaidI Quzhi granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
Trial: NCT05035979
Drug: Ju Yin cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take JY cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
Trial: NCT05035979
Drug: Baidi Quzhi placebo granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Put each bag of medicine in one day into the same container, pour in about 50ml of warm water, stir until the granules are basically dissolved, add some boiled water to dilute, and take it twice.
Trial: NCT05035979
Drug: Ju Yin placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take JY placebo cream 5g evenly applied to the face, negative ion spray at the same time acupoint massage along the meridian, apply 10min, clean the face with water, 3 times a week.
Trial: NCT05658692
Drug: glucocorticoid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10.~Hydrocortisone：For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours).
Trial: NCT05658692
Drug: Muscle relaxant therapy
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
Trial: NCT05658692
Drug: statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Simvastatin: 80mg qd po for not more than 28days;~2. Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died.
Trial: NCT05658692
Drug: Sedative analgesia/muscle relaxant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
Trial: NCT05658692
Drug: inotropes therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.
Trial: NCT05897216
Drug: CKD-501, D745, D150, D029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT06664060
Drug: osteoimplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 lower third molars will be selected and prescribed preoperative treatment with two units of Osteoimplant Complex® 5 days prior to surgery and postoperative treatment with one unit of Osteoimplant® for 8 weeks from the time of surgery. Both nutritional supplements will be administered every 24 hours.
Trial: NCT06664060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 lower wisdom teeth will be selected and prescribed placebo, both preoperatively 5 days prior to surgery and postoperatively for 8 weeks from the time of surgery.
Trial: NCT06662669
Drug: HY-0102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HY-0102 is a recombinant anti-NKG2A humanized monoclonal antibody.
Trial: NCT06662877
Drug: Oxaliplatin + Leucovorin + Fluorouracil (FOLFOX regimen)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m2,d1,iv.drip,Q2W + Leucovorin 400mg/m2,d1,iv.drip,Q2W+ Fluorouracil 2400 mg/m2 civ46h, Q2W
Trial: NCT06428097
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.
Trial: NCT06428097
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
Trial: NCT05025293
Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj
RxNorm normalized name: ZOLEDRONIC ACID 5MG/BAG 100ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100ml Zoledronic acid (5mg/100ml) administered intravenously
Trial: NCT02503280
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (ten 0.5 ml injections of phosphate-buffered saline \[PBS\] and 1% human serum albumin \[HSA\]).
Trial: NCT05604729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution
Trial: NCT05349669
Drug: Jafron use during CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of filter Jafron during CPB
Trial: NCT05390489
Drug: Cascara pulp arabica gayo coffee cream
RxNorm normalized name: arabica coffee oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: extract of cascara pulp arabica gayo coffee
Trial: NCT04908813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Q3W D1
Trial: NCT04908813
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO Q3W D1-D14
Trial: NCT04947033
Drug: TJ210001 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.
Trial: NCT05089539
Drug: Angiotensin Receptor-Neprilysin Inhibition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan \[100 mg\] bid). Continuous treatment was maintained for at least three months.
Trial: NCT05089539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo \[100 mg\] bid). Continuous treatment was maintained for at least three months.
Trial: NCT06669754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04993352
Drug: recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
RxNorm normalized name: endothelial growth factor A, human vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection
Trial: NCT05479175
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen
Trial: NCT03995004
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.
Trial: NCT06502457
Drug: painkiller
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive a painkiller adapted to the service protocol after the fetal heart rate has been recorded.
Trial: NCT06767540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo subcutaneous injection Q2W until week 46.
Trial: NCT06767540
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo subcutaneous injection Q3W until week 45.
Trial: NCT05195034
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 0.9% saline is administered with the same volume at the same speed as the other group.
Trial: NCT05961202
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 20mg qd
Trial: NCT05038488
Drug: MIB-626
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.
Trial: NCT05038488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.
Trial: NCT04632940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered per schedule specified in the arm description.
Trial: NCT04632940
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic deflazacort or equivalent potency of corticosteroids administered orally
Trial: NCT06301165
Drug: TPC induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine. TPC induction chemotherapy regimen (polymeric micellar paclitaxel 200 mg/m2 D1, cisplatin 75 mg/m2 D1, capecitabine 1000 mg/m2/day D1-14, every 3 weeks for 3 cycles).
Trial: NCT06301165
Drug: GP induction chemotherapy
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP induction chemotherapy regimen (gemcitabine 1000 mg/m2 D1/8, cisplatin 80 mg/m2 D1, every 3 weeks for 3 cycles)